Plain-English translation of ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for people with liver cancer who are at high risk of the cancer coming back after surgery. You would receive two rounds of chemotherapy delivered directly to the liver tumor, combined with an immune-boosting medication called Tislelizumab, before your surgery. After surgery heals, you would receive four more rounds of the medication to help prevent recurrence.
Even after successful liver cancer surgery, cancer comes back in more than 70% of patients, often within the first two years—severely affecting quality of life and survival. This trial is testing whether combining chemotherapy with immune therapy before and after surgery can reduce that recurrence rate and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You would first receive two cycles of chemotherapy and immune therapy over several weeks, with the chemotherapy delivered directly into blood vessels feeding the tumor. After these initial treatments, you would have surgery to remove the cancer. Following recovery, you would receive four more cycles of the immune medication as outpatient infusions. Throughout the trial, you would have regular blood tests, imaging scans, and clinic visits to monitor how you're doing and check for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China